Swipe Left For English News
1
药明生物在参与评级的10万余家公司中排名前 1%
2
公司在环境、劳工与人权、商业道德和可持续采购四大评估维度均表现出色
3
公司将坚守可持续发展承诺，做全球医药产业值得信赖的合作伙伴
上海,
2023年12月8日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司凭借在可持续发展领域的杰出成绩，获得国际权威企业可持续发展评估机构EcoVadis授予的最高殊荣“铂金”评级。
EcoVadis作为全球知名的商业可持续发展评级机构，其评级基于专业洞见和实证绩效分析，是全球各规模企业提升商业和价值链长期可持续发展表现的重要参考指标。EcoVadis从四大维度进行评估：环境、劳工与人权、商业道德和可持续采购，药明生物在以上维度均表现优异，在参与评级的10万余家公司中排名前1%。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸获得EcoVadis颁发的'铂金'奖章，这是我们可持续发展战略取得硕果的有力证明。EcoVadis评级为各大跨国公司（尤其是制药公司）评估合作伙伴在长期可持续发展、合作关系等方面提供重要决策依据。我们将继续与员工、客户、供应商和其他利益相关方合作，深耕ESG能力和规模，精益求精，践行ESG战略，继续赋能全球合作伙伴加速发现、开发和生产生物药，造福全球病患。
今年，公司在ESG领域成果显著，6月，公司宣布签署科学碳目标倡议（SBTi）承诺书，稳步迈向净零排放的新里程碑；9月，药明生物加入联合国全球契约组织，通过合作与伙伴关系共同推进更广泛的联合国目标，以履行其对企业和社会可持续发展的承诺；此外，公司还于11月在明晟公司（MSCI）的环境、社会和公司治理（ESG）评级中获得最高AAA评级。
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年6月底，药明生物帮助客户研发和生产的综合项目高达621个，其中包括22个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
1
Ranked in top 1% of the over 100,000 companies evaluated
2
Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement
3
Seen as a trusted partner by global clients for its strong sustainability commitment
Shanghai,
December 8, 2023
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been awarded the EcoVadis Sustainability Rating's Platinum Medal, the highest level of recognition granted to the companies being evaluated.
EcoVadis is a leading ratings organization for the sustainability of supply chains. Businesses of all sizes rely on EcoVadis' expert intelligence and evidence-based ratings to improve the sustainability performance of their companies and their value chains. As a result of WuXi Biologics' outstanding performance across four core themes – Environment, Labor & Human Rights, Ethics, and Sustainable Procurement – it was ranked in the top 1% of the more than 100,000 companies evaluated worldwide.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very proud to receive the Platinum Medal from EcoVadis, which we see as a strong testament to our sustainable business strategy. The EcoVadis Sustainability Rating is an important reference for our partners worldwide – notably all the global pharmaceutical companies – in evaluating sustainability performance and the benefits of collaboration. We will continue to work with clients, suppliers, employees and other stakeholders to enhance our ESG capabilities and advance the common good of the global community.
The EcoVadis recognition follows other notable WuXi Biologics ESG achievements this year. In June, it signed the Science Based Targets initiative (SBTi) commitment letter, a new milestone towards the goal of net-zero. In September, the company became a signatory to the United Nations Global Compact, demonstrating its sustainability commitment. In November, it received an AAA rating from MSCI ESG Ratings.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
